htb supplement: 2018 Vol 19:(1)
New drugs in development
July 2018
www.i-Base.info
Standard Treatment Guidelines
4th Edition 2018
National Malaria Elimination & Aedes Transmitted Disease Control Program
Disease Control Unit Directorate General of Health Services
Tercera versión, 1 de febrero del 2022. Estas orientaciones tienen por objetivo contribuir a que los sistemas de salud prioricen los medicamentos esenciales que deben estar disponibles y ser asequibles para manejar los pacientes en las unidades de cuidado intensivos durante las emergencias de salud
...
. Esta actualización incluye una sección sobre el tratamiento de pacientes graves o críticos, así como nuevos datos sobre la evidencia y la firmeza de las recomendaciones incluidas en versiones anteriores.
more
Updated 10 August 2020
This document presents an essential medicines list (EML) to manage patients in intensive care units (ICUs) with suspected or confirmed COVID-19 diagnosis, which includes active ingredients with dosage form and concentration, and are preferably in the WHO Model Lists of Essent
...
ial Medicines 2019; based on clinical presentations and symptoms identified and prioritized in World Health Organization (WHO) and Surviving Sepsis Campaign (SSC) guidelines and the evidence presented in these guidelines.
more
IBOGA Review No.1 Revue Scientifique du Jésuites d'Afrique de l'Ouest
This report presents three scenarios on the impact of COVID-19 in Africa using economic growth forecasts, mortality and efforts to ameliorate impact through social grants. Likely effects are examined on per capita income, poverty and the attainment of selected Sustainable Development Goals targets.
...
Africa’s development trajectory has suffered a severe setback, with extreme poverty rising in all the scenarios. The pandemic threatens Africa in several ways, and the report provides policy recommendations to reduce vulnerability and strengthen resilience.
more
Erfahrungen im Umgang mit COVID-19-Erkrankten–Hinweise von Klinikern für Kliniker –
The two-year impact report for the Access to COVID-19 Tools (ACT) Accelerator details impact, case studies and timelines of key milestones for the Diagnostics, Therapeutics and Vaccines pillars, as well as the Health Systems and Response Connector.
WHO published guidance for clinicians and health care decision-makers on the use of corticosteroids in patients with COVID-19.
We recommend systemic corticosteroids for the treatment of patients with severe and critical COVID-19. We suggest not to use corticosteroids in the treatment of patients
...
with non-severe COVID-19 as the treatment brought no benefits, and could even prove harmful. Treatment should be under supervision of a clinician.
Corticosteroids are listed in the WHO model list of essential medicines, readily available globally at a low cost. WHO encourages countries to maintain sufficient stocks of corticosteroids to treat COVID-19 and the other disease for which they are effective, while not maintaining excessive stocks which could deny other countries access.
more
General practitioners and pediatricians must know the signs and
symptoms of possible pediatric cancer.